Altogether, our findings are in agreement with previous reports that suggest attenuating IL-1β signaling may offer therapeutic benefit to Alzheimer’s disease patients21, as well as provides a potential mechanism by which PDD005 downregulates IL-1β synthesis and tau protein phosphorylation. Here, IL1B is linked to early-onset autosomal dominant Alzheimer disease.